key: cord-0792853-hqe915ke
authors: Mosig, Axel
title: Letter to the Editor Regarding the recent contribution by Roussel et al. (SARS-CoV-2: Fear Versus Data)
date: 2020-07-03
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2020.106074
sha: 4814d1fc2c08486d8f9d5191dcd63ad76ed6528e
doc_id: 792853
cord_uid: hqe915ke

nan

Dear Editor, significant attention has been drawn to publications about SARS-CoV-2, including the article SARS-CoV-2: fear versus data by Roussel et al. [1] that has been published as a preprint recently. The article has caught some public attention, specifically has it been cited in a public letter by Sucharit Bhakdi, emeritus Head of the Institute for Medical Microbiology and Hygiene at the Johannes-Gutenberg-Universität in Mainz, Germany, to the Chancellor of the Federal Republic of Germany.

I have found severe reasons to doubt the validity of the study by Roussel et al. that should either be adressed by the authors, or at least should not be left uncommented, if the contribution meets standards of publication at all. I have expressed my specific concern in the main file of my letter. I must admit I am surprised how a manuscript with such low standard of validity can get accepted in a peer-review process. I would like to strongly suggest that the paper will be assessed by a statistical expert.

In any case, I hope my Letter will resonate with the editors of the journal. Should the editors decide to not retract the manuscript from the journal, I kindly ask to publish my express of concern in a suitable manner.

With Kind Regards, Axel Mosig Table 2 , however, lack evidence for being comparable to this situation. 32 33 2. The data displayed in Table 3 Given the due reasons for concern about the validity of the study's results and the timely 58 relevance for public discussion and decision making of the topic, I remind to consider my 59 above points, which request the application of common scientific standards for decision 60 making in the medical field.

SARS-CoV-2: Fear Versus Data

Impact of non-pharmaceutical interventions (NPIs) to reduce

COVID-19 mortality and healthcare demand